Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 252

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

Open access
Cummings, Jeffrey L., Cohen, Sharon, van Dyck, Christopher H., Brody, Mark, Curtis, Craig, Cho, William, Ward, Michael, Friesenhahn, Michel, Rabe, Christina, Brunstein, Flavia, Quartino, Angelica, Honigberg, Lee A., Fuji, Reina N., Clayton, David, Mortensen, Deborah, Ho, Carole, Paul, Robert · 2018 · Neurology

Abstract

OBJECTIVE: To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). METHODS: In this phase 2 trial, 431 patients with mild to moderate AD 50 to 80 years of age were randomized 2:1 (crenezumab:placebo). Patients received low-dose subcutaneous crenezumab 300 mg or placebo every 2 weeks (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks. Primary outcome measures were change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog12) and Clinical Dementia Rating-Sum of Boxes scores from baseline to week 73. RESULTS: levels that correlated with crenezumab CSF levels. The overall rate of adverse events was balanced between groups. One case of amyloid-related imaging abnormalities indicative of vasogenic edema or effusions was reported. CONCLUSIONS: Although prespecified criteria for testing treatment effects were not met, these data suggest a potential treatment effect in patients with mild AD treated with high-dose crenezumab. Together with the safety profile for crenezumab, these data support the exploration of crenezumab treatment at even higher doses in patients with early AD. CLINICALTRIALSGOV IDENTIFIER: NCT 01343966. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, for people with AD, crenezumab does not significantly improve cognition or function at 18 months. The study is rated Class II because <80% of enrolled patients completed the study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000005550

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 14

  1. 10.1016/j.jalz.2017.02.001 · DOI · Paper page
  2. 10.1016/j.jalz.2015.08.153 · DOI
  3. 10.1523/JNEUROSCI.0695-06.2006 · DOI
  4. 10.1212/WNL.34.7.939 · DOI · Paper page
  5. 10.1016/0022-3956(75)90026-6 · DOI · Paper page
  6. 10.1001/archneur.65.8.1091 · DOI · Paper page
  7. 10.1002/ana.410310303 · DOI
  8. 10.1097/WAD.0b013e3181f883b7 · DOI
  9. 10.1097/00002093-199700112-00003 · DOI · Paper page
  10. 10.1097/00002093-199700112-00005 · DOI · Paper page
  11. 10.1016/j.jalz.2013.11.008 · DOI
  12. Sevigny J, Chiao P, Williams L, Miao X, O'Gorman J. Randomized, double-blind, phase 1b study of BIIB037, an anti-amyloid beta monocloncal antibody, in patients with prodromal or mild Alzheimer's disease. Neurodegener Dis 2015;15(suppl 1):311.
  13. Lasser R, Ostrowitzki S, Scheltens P, et al. Efficacy and safety of gantenerumab from the phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD. JPAD 2015;2:275.
  14. 10.1097/SMJ.0b013e318181d5b5 · DOI

Cited by

See all 252

Metadata

Authors
Cummings, J. L., Cohen, S., van Dyck, C. H., Brody, M., Curtis, C., Cho, W., Ward, M., Friesenhahn, M., Rabe, C., Brunstein, F., Quartino, A., Honigberg, L. A., Fuji, R. N., Clayton, D., Mortensen, D., Ho, C., & Paul, R.
Venue
Neurology
Published
2018-05-22
Volume
90
Issue
21
Pages
e1889-e1897
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2800202520
Cited by
252
References
17
FWCI
18.85
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000005550
The paper
Cummings, J. L., Cohen, S., van Dyck, C. H., Brody, M., Curtis, C., Cho, W., Ward, M., Friesenhahn, M., Rabe, C., Brunstein, F., Quartino, A., Honigberg, L. A., Fuji, R. N., Clayton, D., Mortensen, D., Ho, C., & Paul, R. (2018). ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000005550

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.